Skip to main content
. 2015 Feb 23;33(10):1197–1213. doi: 10.1200/JCO.2014.55.9575

Table 1.

Antibodies Currently in Clinical Development for Glioblastoma

Agent Mechanism Phase Disease Type Response Rate (%) PFS (months) PFS6 (%) OS (months) Combination Reference ClinicalTrials.gov No.
Bevacizumab VEGF-A–blocking antibody II rGBM 28.2 42.6 8.6 — Friedman et al9
Bevacizumab VEGF-A–blocking antibody II rGBM 37.8 50.3 8.1 Irinotecan Friedman et al9
Bevacizumab VEGF-A–blocking antibody II rGBM 60.9 30 9.3 Irinotecan Vredenburgh et al104
Bevacizumab VEGF-A–blocking antibody II rGBM 57 46 9.8 Irinotecan Vredenburgh et al11
Bevacizumab VEGF-A–blocking antibody II rGBM 35 29 7.2 — Kreisl et al10
Bevacizumab VEGF-A–blocking antibody II rGBM 33 46.5 8.3 Irinotecan, carboplatin Reardon et al45
Bevacizumab VEGF-A–blocking antibody II rGBM 28 18.8 8.6 Temozolomide Desjardins et al47
Bevacizumab VEGF-A–blocking antibody II rGBM 24.5 25 6.5 — Raizer et al52
Bevacizumab VEGF-A–blocking antibody II rGBM 23 44.4 10.7 Etoposide Reardon et al46
Bevacizumab VEGF-A–blocking antibody II rGBM 0 0 2.9 Temozolomide Reardon et al44
Bevacizumab VEGF-A–blocking antibody II rGBM 0 7.7 4.4 Etoposide Reardon et al44
Bevacizumab VEGF-A–blocking antibody II rGBM 26 33 6.7 Irinotecan, cetuximab Hasselbalch et al53
Bevacizumab VEGF-A–blocking antibody II rGBM 50 29.2 10.5 Erlotinib Sathornsumetee et al54
Bevacizumab VEGF-A–blocking antibody III nGBM 10.7 15.7 Temozolomide, radiotherapy Gilbert et al13
Bevacizumab VEGF-A–blocking antibody III nGBM 10.6 Temozolomide, radiotherapy Chinot et al12
Bevacizumab VEGF-A–blocking antibody II nGBM — 13 85.1 23 Temozolomide, radiotherapy Narayana et al56
Bevacizumab VEGF-A–blocking antibody II nGBM — 14.2 — 21.2 Temozolomide, radiotherapy, irinotecan Vredenburgh et al57
Bevacizumab VEGF-A–blocking antibody II nGBM — 13.6 88 19.6 Temozolomide, radiotherapy Lai et al25
Bevacizumab VEGF-A–blocking antibody Retrospective rGBM 83 22 7.0 Carboplatin, etoposide Francesconi et al164
Bevacizumab VEGF-A–blocking antibody Retrospective rGBM 42 42 7.9 — Chamberlain et al165
Bevacizumab VEGF-A–blocking antibody Retrospective rGBM — 41* 9.0* Irinotecan, carboplatin, lomustine, etoposide Nghiemphu et al166
Bevacizumab VEGF-A–blocking antibody Retrospective rGBM 67.6 63.7 10.7 Irinotecan Zuniga et al41
Bevacizumab VEGF-A–blocking antibody Retrospective rGBM 77 — 6.3 Irinotecan Ali et al167
Bevacizumab VEGF-A–blocking antibody Retrospective rGBM — 17 7.1 Irinotecan Kang et al168
Bevacizumab VEGF-A–blocking antibody Retrospective rGBM Irinotecan Bokstein et al169
Bevacizumab VEGF-A–blocking antibody Retrospective rGBM 40* — — Carboplatin, irinotecan, etoposide Pope et al170
Bevacizumab VEGF-A–blocking antibody Retrospective rGBM 9/21 MG Irinotecan Stark-Vance et al171
Bevacizumab VEGF-A–blocking antibody Retrospective rGBM 50 0 1.5 — Scott et al172
Bevacizumab VEGF-A–blocking antibody Retrospective rGBM 19 14 5.2 Irinotecan, carboplatin, or temzolomide Scott et al172
Bevacizumab VEGF-A–blocking antibody Retrospective rGBM 29* 29* 7.8* Irinotecan, carboplatin Goldlust et al173
Bevacizumab VEGF-A–blocking antibody Retrospective rGBM — 42* — Irinotecan, carboplatin, lomustine, etoposide Norden et al174
Bevacizumab VEGF-A–blocking antibody Retrospective rGBM 0* — — Carboplatin, irinotecan, carmustine, lomustine, erlotinib, etoposide Quant et al70
Aflibercept VEGF-A, VEGF-B, PlGF decoy receptor II rGBM 18 7.7 9.1 — De Groot et al62
Aflibercept VEGF-A, VEGF-B, PlGF decoy receptor I† nGBM Temozolomide, radiotherapy NCT00650923
Olaratumab (IMC-3G3) Antibody against PDGFR-α II† rGBM — NCT00895180
Ramucirumab (IMC-1121B) Antibody against VEGFR-2 II† rGBM — NCT00895180

Abbreviations: MG, malignant glioma; nGBM, newly diagnosed glioblastoma; OS, overall survival; PDGFR-α, platelet-derived growth factor receptor alpha; PFS, progression-free survival; PFS6, 6-month PFS; PlGF, placental growth factor; rGBM, recurrent glioblastoma; VEGF-A, vascular endothelial growth factor A; VEGFR-2, vascular endothelial growth factor receptor 2.

*

For overall group.

†

Ongoing trial.